Key facts
- This page summarizes David E. Lazar's Form 4 filing for OPGEN INC (OPGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Aug 2024, 17:25.
David E. Lazar - 30 Jul 2024 Form 4 Insider Report for OPGEN INC (OPGN)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- OPGN
- Reported as of
- 30 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Aug 2024, 17:25:45 UTC
- Prior SEC filing
- 13 May 2024
- Next SEC filing
- 21 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David E. Lazar
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David E. Lazar filed Form 4 for OPGEN INC (OPGN) on 01 Aug 2024.
Change
- Previous filing in this sequence was filed on 13 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OPGN
transaction
Derivative
Series E Convertible Preferred Stock
Sale
- Transaction value
- Shares
- -550,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,320,000
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On July 30, 2024, David E. Lazar (the "Reporting Person") entered into a securies purchase agreement with AEI Capital Group, a third party, pursuant to which the Reporting Person sold (i) 550,000 shares of Series E Convertible Preferred Stock (the "Series E Preferred Stock") of OpGen, Inc. (the "Company") and (ii) the rights to acquire an additional 2,450,000 shares of Series E Preferred Stock for $2,450,000 pursuant to an agreement between the Reporting Person and the Company.
Footnote F2
The shares of Series E Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
Footnote F3
The Series E Preferred Stock is perpetual and therefore has no expiration date.